Ocular Therapeutix

^{Priced, Nasdaq: OCUL}

Develops eye therapies using a sustained-release hydrogel platform.

Industry: Health Care

First Day Return: +1.2%

OCUL

Develops eye therapies using a sustained-release hydrogel platform.

IPO News for Ocular Therapeutix

Year's fourth eye-focused biotech EyeGate Pharmaceuticals sets terms for $25 million IPO 09/14/14
Biotech EyeGate Pharmaceuticals files for a $29 million IPO 07/30/14
US IPO Pricing Recap: The crazy chicken flies while 8 IPOs trade down or flat 07/25/14

IPO Data
IPO Date	07/24/2014
Offer Price	IPO Intelligence Only
Price Range	IPO Intelligence Only
Offer Shares (mm)	IPO Intelligence Only
Deal Size ($mm)	$65
Lock-Up Date	IPO Intelligence Only
Street Research	IPO Intelligence Only

Underwriters
IPO Intelligence Only

Company Data
Website www.ocutx.com
Headquarters	Bedford, MA, United States
Founded	2006
Employees at IPO	58

IPO News for Ocular Therapeutix

Ocular Therapeutix (OCUL) Performance